Ascendis Pharma - Stock Price History | ASND

Historical daily share price chart and data for Ascendis Pharma since 2021 adjusted for splits. The latest closing stock price for Ascendis Pharma as of September 27, 2021 is 163.41.
  • The all-time high Ascendis Pharma stock closing price was 182.76 on December 14, 2020.
  • The Ascendis Pharma 52-week high stock price is 183.98, which is 12.6% above the current share price.
  • The Ascendis Pharma 52-week low stock price is 109.36, which is 33.1% below the current share price.
  • The average Ascendis Pharma stock price for the last 52 weeks is 146.74.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Ascendis Pharma Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 144.2238 141.1300 182.7600 97.0100 166.7800 19.88%
2019 107.6588 64.8400 139.1200 62.1500 139.1200 122.06%
2018 63.4760 39.8000 76.2800 38.9800 62.6500 56.39%
2017 29.2030 19.9100 40.3800 19.9100 40.0600 97.92%
2016 17.3994 18.0300 21.3100 12.2500 20.2400 10.48%
2015 18.1703 18.8300 21.4600 15.8350 18.3200 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.216B $0.008B
Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29